Further Vyvanse shortages forecast

Takeda Pharmaceuticals Australia warns that a fourth strength of its ADHD medication, Vyvanse, will be in short supply   Worldwide shortages of Takeda’s Vyvanse (lisdexamfetamine dimesilate) products are expected to continue until late April, as a result of manufacturing issues, the company says.  In an update issued by the Therapeutic Goods Administration (TGA) today (18